Compare JHX & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JHX | AXSM |
|---|---|---|
| Founded | 1888 | 2012 |
| Country | Ireland | United States |
| Employees | 7500 | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 12.0B |
| IPO Year | N/A | 2015 |
| Metric | JHX | AXSM |
|---|---|---|
| Price | $25.70 | $240.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 17 |
| Target Price | $27.83 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 7.8M | 867.2K |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.06 | $57.24 |
| Revenue Next Year | $14.50 | $55.88 |
| P/E Ratio | $122.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.46 | $96.09 |
| 52 Week High | $29.83 | $260.19 |
| Indicator | JHX | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 51.70 |
| Support Level | $19.15 | $236.44 |
| Resistance Level | $27.06 | $260.19 |
| Average True Range (ATR) | 0.86 | 8.87 |
| MACD | -0.03 | -1.82 |
| Stochastic Oscillator | 62.59 | 16.25 |
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Following the Azek acquisition in 2025, it also produces wooden composite decking materials, siding trims, and accessories for outdoor areas including stair and deck railing. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.